Skip to main content

Table 3 Initial diagnosis and current period lab measurements of glycaemic control per treatment strategy

From: A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies

Variable

Initial diagnosis

Current period

Treatment Strategy

Treatment Strategy

P

All

A

B

C

All

A

B

C

Patients n (%)

1189 (100%)

722 (60.7%)

334 (28.1%)

133 (11.2%)

1189 (100%)

241 (20.3%)

478 (40.2%)

470 (39.5%)

 

Full analysis set, n

572 (100%)

359 (62.8%)

151 (26.4%)

62 (10.8%)

1120 (100%)

225 (20.1%)

452 (40.4%)

443 (39.6%)

 

HbA1c %

Median (IQR)

7.8 (7.0–9.0)

7.5 (6.8–8.2)

8.6 (7.7–10.0)

10.0 (8.5–11.7)

6.9 (6.3–7.5)

6.4 (6.0–7.0)

6.7 (6.3–7.2)

7.3 (6.7–8.0)

< 0.001b

Mean ± SD

8.4 ± 1.4

7.5 ± 1.6

8.3 ± 1.1

9.3 ± 2.2

7.1 ± 1.2

6.6 ± 1.0

6.9 ± 1.1

7.5 ± 1.2

 

Adjustedc mean ± SD

 

8.1 ± 0.2

8.3 ± 0.1

8.5 ± 0.1

 

7.0 ± 0.1

7.0 ± 0.1

7.2 ± 0.1

0.771

 < 6.5%

42 (7.0%)

38 (10.0%)

3 (1.0%)

1 (1.0%)

339 (30.0%)

115 (51.1%)

159 (35.2%)

65 (14.7%)

< 0.001a

 [6.5–7.0%)

73 (12.0%)

65 (18.0%)

8 (5.0%)

0 (0%)

259 (23.0%)

52 (23.1%)

115 (25.4%)

92 (20.7%)

 

 < 7.0%

115 (19.0%)

103 (28.0%)

11 (6.0%)

1 (1.0%)

598 (53.0%)

167 (74.2%)

274 (60.6%)

157 (35.4%)

 

 [7.0–7.5%)

92 (16.0%)

73 (20.0%)

16 (10.0%)

3 (4.0%)

218 (19.0%)

34 (15.1%)

94 (20.8%)

90 (20.3%)

 

 [7.5–8.0%]

119 (20.0%)

81 (22.0%)

30 (19.0%)

8 (12.0%)

149 (13.0%)

14 (6.2%)

42 (9.3%)

93 (21.0%)

 

 > 8.0%

246 (43.0%)

102 (28.0%)

94 (62.0%)

50 (80.0%)

155 (13.0%)

10 (4.5%)

42 (9.3%)

103 (23.3%)

 

FPG mg/dl

Median (IQR)

177 (142–234)

160 (135–200)

200 (160–259)

240 (186–350)

126 (110–150)

120 (107–135)

126 (110–150)

130 (111–161)

< 0.001b

Mean ± SD

201 ± 85

179 ± 63

221 ± 82

280 ± 133

136 ± 42

126 ± 32

135 ± 41

141 ± 46

 

Adjustedc mean ± SD

 

189.4 ± 6.9

201.1 ± 4.7

206.3 ± 5.1

 

134.8 ± 3.0

133.1 ± 2.0

138.6 ± 2.1

0.180

Median (IQR)

NA

NA

NA

NA

144 (130–160)

152 (138–178)

170 (145–200)

144 (130–160)

<  0.001b

Adjustedc mean ± SD

NA

NA

NA

NA

 

163.2 ± 3.7

166.0 ± 2.5

169.6 ± 2.6

0.375

  1. aChi – square independence test,
  2. bKruskal Wallis test
  3. cMean values adjusted for age, duration of diabetes, body mass index and family history of diabetes
  4. Kruskal Wallis post-hoc pairwise comparisons between groups
  5. •HbA1c % vs Treatment Group:
  6. Treatment Group A vs Treatment Group B: p < 0.001.
  7. Treatment Group A vs Treatment Group C: p < 0.001.
  8. Treatment Group C vs Treatment Group B: p < 0.001
  9. •FBG vs Treatment Group:
  10. Treatment Group A vs Treatment Group B: p = 0.003
  11. Treatment Group A vs Treatment Group C: p < 0.001.
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us